Salesforce's Acquisition Strategy: Promise vs. Proof

What happened

Salesforce's recent acquisitions of Informatica and pending Fin aim to bolster its Agentforce AI platform and address concerns over slowing organic growth, as highlighted in a Motley Fool article. However, the DeepValue report assigns a WAIT rating, emphasizing that while the company's cRPO grew 14% and AI ARR reached $3.4B, these figures are partly acquisition-aided and mask the need for clean organic acceleration. The market remains skeptical, with the stock down 39% from its peak, reflecting doubts about whether AI monetization can offset seat compression from generative AI. The upcoming Q2 and Q3 FY27 results are critical: cRPO must sustain 14%+ and organic subscription growth must re-accelerate to validate the thesis. Until then, the stock's attractive entry near $150 offers limited margin of safety given the risk of further multiple compression if growth disappoints.

Implication

The next six months will determine whether Salesforce's AI strategy delivers organic growth or remains acquisition-dependent. If cRPO holds 14%+ and Agentforce ARR grows without acquisition aid, the stock could re-rate toward $195. Conversely, if cRPO slips below 12% or management cuts 2H guidance, a re-rate to $145 is plausible. The debt-funded $25B buyback reduces balance-sheet flexibility, adding downside risk. Investors should monitor cRPO trends and production deployment evidence before committing capital.

Thesis delta

The thesis shifts from cautious optimism to a more neutral wait-and-see stance. The recent article adds a positive spin on acquisitions, but the core risk of organic growth stagnation remains unaddressed. Until Q2FY27 cRPO data is released, the uncertainty outweighs the potential reward.